Foxp3 Serum Levels in Contrast Induced Nephrophaty Patients After the Administration of Contrast Media

Percutaneous Coronary Intervention (PCI) procedure increases the risk of inflammation risk and represents adverse effects to immune system in the human body. One of the functions in the human body in maintaining the balance of immune system is Foxp3 of regulatory T cells and the function of Foxp3 is seldom to be the subject of study in coronary patients from the administration of contrast agents after PCI. This study was conducted to analyze the comparison Foxp3 levels of regulatory T cells in blood serums in patients who experienced contrast induced nephrophaty (CIN) after PCI procedure for both the CIN group and the non-CIN group. The population of coronary patients after PCI. The sample size was 20 patients that consisted of 10 patients who experienced CIN and 10 patients who experienced the CIN group. Categorization of both the CIN and non-CIN group used Kidney Disease Improving Global Outcomes (KDIGO) and detection of Foxp3 levels in blood serums using Enzyme-linked immunosorbent assay (ELISA) technique. Result of this study indicated that the characteristics of patients between the CIN group and the non-CIN group did not reveal significant difference, except for the characteristic of age. Results of the analysis by using statistical pair and non-pair t-test showed that patients for both the CIN group and non-CIN group experienced significant reduction of Foxp3 levels of regulatory T cells in their blood serums. This indicated that the PCI procedure indeed led to inflammation and Foxp3 levels and it could not be used as the specific marker for CIN incidence, but it should be mediated by the inflammation marker.